- Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe - The EC approval ...
(RTTNews) - Incyte (INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel, a platinum-based chemotherapy regimen, for the ...
The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY) and MacroGenics (MGNX), due to issues found at a ...
All right. Welcome back to the 46th Annual TD Cowen Healthcare Conference. Really happy to have the next session here with -- I'm Marc Frahm from the biotech team here at TD Cowen, and we're really ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results